Multiomic quantification of the KRAS mutation dosage improves the preoperative prediction of survival and recurrence in patients with pancreatic ductal adenocarcinoma
Abstract Most cancer mutation profiling studies are laboratory-based and lack direct clinical application. For clinical use, it is necessary to focus on key genes and integrate them with relevant clinical variables. We aimed to evaluate the prognostic value of the dosage of the KRAS G12 mutation, a...
Saved in:
Main Authors: | Won-Gun Yun, Daeun Kim, Youngmin Han, Wooil Kwon, Seong-Geun Lee, Jin-Young Jang, Daechan Park |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2025-01-01
|
Series: | Experimental and Molecular Medicine |
Online Access: | https://doi.org/10.1038/s12276-024-01382-0 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
p53 dosage can impede KrasG12D- and KrasQ61R-mediated tumorigenesis.
by: Özgün Le Roux, et al.
Published: (2024-01-01) -
Pancreatic Ductal Organoids React Kras Dependent to the Removal of Tumor Suppressive Roadblocks
by: Lukas Perkhofer, et al.
Published: (2019-01-01) -
Multiomic machine learning on lactylation for molecular typing and prognosis of lung adenocarcinoma
by: Mengmeng Hua, et al.
Published: (2025-01-01) -
Vitamin K‐dependent gamma‐carboxyglutamic acid protein 1 promotes pancreatic ductal adenocarcinoma progression through stabilizing oncoprotein KRAS and tyrosine kinase receptor EGFR
by: Zheng Wu, et al.
Published: (2025-01-01) -
Association between preoperative exercise tolerance and unplanned readmission in patients who underwent pancreatectomy for pancreatic ductal adenocarcinoma: a retrospective analysis
by: Makoto Onji, et al.
Published: (2025-01-01)